PUBLISHER: The Business Research Company | PRODUCT CODE: 1945483
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945483
Lipid panel testing refers to a blood test that measures the levels of various lipids or fats in the blood. This test is commonly used to assess an individual's risk of developing cardiovascular disease.
The main products and services related to lipid panel testing include devices, kits, and services. Devices, such as analyzer machines, are the equipment used to perform lipid panel testing. The various prescription modes for lipid panel testing include prescription-based testing and over-the-counter (OTC) based testing. Lipid panel testing is applied in various conditions such as hyperlipidemia, hypertriglyceridemia, familial hypercholesterolemia, hypo-lipoproteinamia, Tangier disease, atherosclerosis, and others. The diverse end users of lipid panel testing products and services encompass hospitals, specialty clinics and physician offices, pathology laboratories, diagnostic clinics, ambulatory surgical centers, reference laboratories, academic and research institutes, and others.
Tariffs are impacting the lipid panel testing market by increasing costs of imported diagnostic reagents, testing kits, automated analyzers, and electronic components used in laboratory and point-of-care systems. Diagnostic laboratories and healthcare providers in North America and Europe are most affected due to reliance on imported consumables and devices, while Asia-Pacific faces cost pressures on test kit manufacturing and exports. These tariffs are raising testing costs and affecting procurement cycles. However, they are also encouraging local production of diagnostic kits, regional reagent manufacturing, and supply chain diversification.
The lipid panel testing market research report is one of a series of new reports from The Business Research Company that provides lipid panel testing market statistics, including lipid panel testing industry global market size, regional shares, competitors with a lipid panel testing market share, detailed lipid panel testing market segments, market trends and opportunities, and any further data you may need to thrive in the lipid panel testing industry. This lipid panel testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The lipid panel testing market size has grown strongly in recent years. It will grow from $11.61 billion in 2025 to $12.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, expansion of routine health screening programs, growing awareness of cholesterol management, adoption of automated laboratory diagnostics, improved access to diagnostic services.
The lipid panel testing market size is expected to see strong growth in the next few years. It will grow to $17.79 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing focus on preventive healthcare, rising demand for home diagnostics, integration of digital health platforms, growing use of AI-assisted diagnostic interpretation, expansion of population health screening initiatives. Major trends in the forecast period include increasing adoption of point-of-care lipid testing, rising use of automated lipid analyzers, growing demand for preventive cardiovascular screening, expansion of home-based lipid testing kits, enhanced focus on early risk assessment.
The anticipated increase in cardiovascular and diabetic diseases is poised to drive the growth of the lipid panel testing market. Cardiovascular disease, a cluster of conditions affecting the heart and blood vessels, along with diabetes, a metabolic disorder impacting insulin production and leading to elevated blood sugar levels, collectively contribute to the demand for lipid panel testing. This diagnostic tool is crucial for identifying individuals at risk of developing cardiovascular diseases or those already affected. Additionally, it aids in monitoring treatment effectiveness, enabling healthcare providers to adjust treatment plans to attain target lipid levels and mitigate the risk of further ailments. For example, in September 2025, data from the American College of Cardiology, a United States-based nonprofit medical association, indicated that global deaths due to cardiovascular diseases reached approximately 19.2 million in 2023. Consequently, the escalating prevalence of cardiovascular and diabetic diseases is expected to propel the lipid panel testing market forward.
Leading companies operating in the lipid panel testing market are increasingly concentrating on the development of advanced diagnostic solutions, including lipoprotein(a)-based assays, to strengthen cardiovascular risk evaluation. An Lp(a)-based assay is a diagnostic test that measures lipoprotein(a) levels in the blood, helping clinicians identify individuals with a higher risk of cardiovascular disease and enabling more tailored treatment approaches. For instance, in May 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and diagnostics company, introduced the Tina-quant Lp(a) RxDx assay after obtaining Breakthrough Device Designation from the United States Food and Drug Administration. This assay quantifies the number of Lp(a) particles per litre of blood, providing a standardized and clinically actionable biomarker for cardiovascular risk assessment. Designed for integration with Roche's existing serum work area systems and cobas platforms, the assay supports informed clinical decision-making related to Lp(a)-lowering therapies, enhances diagnostic precision, and encourages broader adoption of personalized lipid management approaches.
In July 2024, Hydreight Technologies Inc., a United States-based provider of at-home blood testing services, entered into a partnership with a national laboratory to broaden its testing offerings. Through this collaboration, Hydreight aims to expand access to a wider portfolio of laboratory tests across all fifty states in the United States, thereby improving patient convenience, accessibility, and turnaround times. The national laboratory involved is a United States-based provider of clinical laboratory testing services, specializing in comprehensive diagnostic testing and detailed reporting for both healthcare professionals and individual consumers.
Major companies operating in the lipid panel testing market are Abbott Laboratories, Beckman Coulter Inc., F. Hoffmann-La Roche Ltd., Randox Laboratories Ltd., Thermo Fisher Scientific Inc., PTS Diagnostics, Quest Diagnostics Incorporated, Alere Inc., Boston Heart Diagnostics Corporation, Eurofins Scientific SE, Spark Diagnostics Pvt Ltd., Everlywell Inc., Horiba ABX SAS, Siemens Healthcare GmbH, Nova Biomedical Corporation, Bio-Rad Laboratories Inc., Danaher Corporation, DiaSorin S.p.A., EKF Diagnostics Holdings plc, Ortho Clinical Diagnostics LLC
North America was the largest region in the lipid panel testing market in 2025. Asia-Pacific is expected to be the fastest growing region in the global lipid panel testing market during the forecast period. The regions covered in the lipid panel testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the lipid panel testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The lipid panel testing market consists of revenues earned by entities by providing high cholesterol testing and lipoprotein analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The lipid panel testing market also includes sales of cholesterol test kit, lipid profile analyzer, and cholesterol self-test kit which are used in providing testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Lipid Panel Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses lipid panel testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for lipid panel testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lipid panel testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.